What is the diagnosis and treatment for Systemic Capillary Leak Syndrome (SCLS)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

Diagnosis of Systemic Capillary Leak Syndrome (SCLS)

  • SCLS is characterized by increased capillary permeability to proteins and fluid extravasation from blood vessels into surrounding tissues and body cavities, leading to hypotension, generalized anasarca, pleural effusions, and pericardial effusions 1
  • Diagnosis of SCLS can be challenging and is sometimes a diagnosis of exclusion, requiring the exclusion of secondary diseases, especially when a serum monoclonal immunoglobulin is present, or when there is a relapsing disease, no initial lung involvement, or preserved consciousness despite low blood pressure 2
  • Clinical presentation of SCLS includes hypotension, edema, hemoconcentration, and hypoalbuminemia, and can be misdiagnosed as hypovolemic shock, septic shock, polycythemia vera, or angioedema 3

Treatment of Systemic Capillary Leak Syndrome (SCLS)

  • Treatment of SCLS includes corticosteroids, diuretics, albumin, immunoglobulins, and crystalloids 1
  • Acute episodes of SCLS are treated with vasopressor therapy and judicious fluid replacement, while patients with Clarkson's disease may be treated with intravenous immunoglobulins between episodes 2
  • Intensive care and supportive therapy constitute the mainstay of the treatment, along with judicious use of crystalloids and colloids such as dextran and starch during the leak phase 4
  • The use of proning, steroids, and intravenous immunoglobins may be beneficial in patients with SCLS, and extracorporeal membrane oxygenation appears to be an excellent strategy to surmount the impediments of the leak and post-leak phase of SCLS, especially in patients with severe or refractory hypoxemia 4
  • Prophylactic treatment with β2 agonists, methylxanthines, and intravenous immunoglobulins may improve survival rates in patients with SCLS 3

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.